In This Issue  by unknown
1Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
In ThIs Issue
•	 Validation of a histology-
Independent Prognostic 
Gene signature for early-
stage, non–small-Cell 
Lung Cancer Including 
stage IA Patients
OPTOMETRY AND VISION SCIENCE
Copyright © 2013 American Academy of Optometry
adjuvant therapy, collected at the University Health 
Network, in Toronto, Canada. Five-year overall survival 
was estimated using the Kaplan–Meier method, and 
log-rank test was used to assess the prognostic effect 
of the classifier. High- and low-risk patients were 
identified by the classifier with significant difference 
in overall survival (hazard ratio [HR] = 1.92, p = 
0.012). This classifier was prognostic for 127 stage I 
patients (HR = 2.17, p = 0.018), 48 stage IA patients 
(HR = 5.61; p = 0.014), and both adenocarcinoma and 
squamous cell carcinoma cases (HR = 1.76, p = 0.058; 
HR = 4.19, p = 0.045, respectively). The prognostic 
accuracy of the 15-gene classifier was validated in 
early-stage NSCLC patients, including stage IA, and in 
different histological subtypes. The authors suggested 
its promising potential in identifying patients who will 
benefit from adjuvant chemotherapy independent of 
stage and histology. (p. 59)
•	 erk/MAP-Kinase 
signaling Pathway 
and neuroendocrine 
Differentiation of non–
small-Cell Lung Cancer
The authors set out to determine the molecular pathways 
involved in neuroendocrine differentiation (NED) of 
non–small-cell lung cancer (NSCLC) and its clinical 
significance. Using NSCLC cell line, NCI-H157, 
they found that activation of Erk1/2-MAPK signal 
transduction pathway and inhibition of Akt signaling 
pathway were associated with NED. The findings were 
further confirmed by using specific Erk1/2-MAPK 
pathway activator (Pb2+) and inhibitors (siRNA-
Erk1/2, and U0126), and Akt pathway inhibitor 
(LY294002). The Erk1/2-MAPK pathway was found 
to be essential for NED of NSCLC and was supported 
by immunohistochemical staining results that showed 
high positivity of phospho-Erk1/2 in NSCLC tumors 
with NED versus other neuroendocrine lung tumors. 
To conclude, this was the first report of a potential 
role of Erk1/2-MAPK pathway in NED of NSCLC. 
Further studies are warranted to dissect the pathway 
and determine molecular targets of the pathway for the 
treatment of NSCLC with NED. (p. 50)
In ThIs Issue
A 15-gene prognostic classifier, developed from mRNA expression 
profiling of tumor samples collected in the NCIC CTG JB.10 trial, 
was previously validated in silico in four large public non–small-
cell lung cancer (NSCLC) expression data sets. The present study 
further evaluated its performance in an independent cohort of 181 
snap-frozen samples from stage I and II NSCLC patients without 
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•	 Poor survival of early-stage 
Lung Carcinoma Predicted 
by epigenetic Inactivation 
of microRnA-34b/c
with methylated miR-34b/c in cell lines and primary 
tumors, especially when TP53 mutation was present. 
Significantly shorter disease-free survival and overall 
survival were observed in patients with high levels of 
methylated miR-34b/c versus those with low levels or 
nonmethylated miR-34b/c. The findings indicated the 
prognostic value of DNA methylation of miR-34b/c 
in early-stage lung cancer. Lung AC cell lines with 
re-expressed miR-34b/c were also less aggressive, with 
reduced cell proliferation, migration, and invasion.
Nadal E, Chen G, Gallegos M, et al. Epigenetic 
inactivation of microRNA-34b/c predicts poor disease-
free survival in early stage lung adenocarcinoma. Clin 
Cancer Res, doi:10.1158/1078-0432.ccr-13–0736 (2013).
mutation status as well as thymidylate synthase RNA 
level were also analyzed. The findings revealed 2.7% 
of cases with an EML4-ALK+ transcript (54.5% of V1, 
10.0% of V2, 34.0% of V3, and 1.5% of V5a variants). 
The majority of EML4-ALK+ NSCLC tumors were 
adenocarcinoma (94%). Significantly different level of 
ALK expression was found between different EML4-
ALK+ variants and individual tumors. Concurrent 
EGFR or KRAS mutation was only identified once 
for each case. Median thymidylate synthase RNA 
level was significantly lower in EML4-ALK+ NSCLC 
tumors versus those without EML4-ALK (p<0.001). 
In conclusion, this panel of reverse transcription 
polymerase chain reaction assays detects EML4-
ALK+ variants and ALK expression in formalin-fixed, 
paraffin-embedded NSCLC specimens. It might be 
useful as an addition to the standard fluorescence in situ 
hybridization assay for improved evaluation of biology 
and response to ALK inhibitors. (p. 18)
•	 Large-scale screening 
and Molecular 
Characterization of 
EML4-ALK Fusion Variants 
in Archival non–small-
Cell Lung Cancer 
Tumor specimens using 
Quantitative Reverse 
Transcription Polymerase 
Chain Reaction Assays
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This study aimed to determine and characterize variants of 
echinoderm microtubule-associated protein-like 4 anaplastic 
lymphoma kinase (EML4-ALK) fusion in 7344 formalin-fixed, 
paraffin-embedded non–small-cell lung cancer (NSCLC) specimens 
of North American patients by using a panel of quantitative reverse 
transcription polymerase chain reaction assays. EGFR and KRAS 
The microRNA-34b/c (miR-34b/c) targets genes in cell cycle, 
apoptosis, and invasion in lung adenocarcinoma (AC) and acts as a 
tumor suppressor. Nadal et al. investigated the clinical impacts of 
miR-34b/c methylation in patients with early-stage lung AC and the 
role of miR-34b/c re-expression in lung AC in vitro. Of 15 lung AC 
cell lines and 140 primary tumors of early-stage lung AC, miR-34b/c 
methylation was found in 40% cell lines and 46% primary tumors. 
Significantly decreased miR-34b/c expression was associated 
•	 Adolescents’ Weight and 
socioeconomic status 
May Affect Their Risk of 
Developing esophageal 
and Gastric Cancer Later 
in Life
52 had combined EAC and gastroesophageal junction 
adenocarcinoma (GEJAC). The association of increased 
risk in the combined EAC and GEJAC group with an 
adolescent body mass index of 85th percentile or more 
(hazard ratio, 2.1; p=.032) reflected that being overweight 
and obese could have a huge impact at younger ages and 
it is unclear whether weight loss would minimize the 
risk. Further follow-up of the current study is needed to 
assess whether the association of adolescent overweight is 
stronger with EAC or GEJAC.
Levi Z, Kark JD, Shamiss A, et al. Body mass index 
and socioeconomic status measured in adolescence, 
country of origin, and the incidence of gastroesophageal 
adenocarcinoma in a cohort of 1 million men. Cancer 
2013;119:4086–4093.
Levi and colleagues from Rabin Medical Center in Israel discovered 
that overweight adolescents have 2.1-fold higher risk of developing 
esophageal adenocarcinoma (EAC) later in life compared with those 
with normal weights, according to their study published in Cancer. 
A million Israeli adolescent males (average age, 17 years) had their 
body mass index measured and were followed up for an average of 
18.8 years. Participants who later developed cancer were identified 
from the national cancer registry. Of the 182 cancer cases documented, 
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CRTC1 at chromosome 19, BARX1 at chromosome 
9, and FOXP1 at chromosome 3. The fourth variant, 
FOXF1 at chromosome 16, was previously associated 
with Barrett’s esophagus and is hereby found to be also 
linked to esophageal adenocarcinoma. Further studies 
are warranted to translate this finding into diagnostic and 
therapeutic measures for esophageal cancers.
Levine DM, Ek WE, Zhang R, et al. A genome-
wide association study identifies new susceptibility 
loci for esophageal adenocarcinoma and Barrett’s 
esophagus. Nat Genet, doi:10.1038/ng.2796. http://
www.nature.com/ng/journal/vaop/ncurrent/abs/
ng.2796.html#supplementary-information (2013).
•	 A Genomics-Based 
Classification of human 
Lung Tumors: The Clinical 
Lung Cancer Genome 
Project (CLCGP) and 
network Genomic 
Medicine (nGM)
histological subtypes varied significantly. As a result 
of combined histopathological and genomic analysis, 
large cell carcinomas were reassigned to therapeutically 
relevant groups, for example, adenocarcinoma or 
squamous cell carcinoma. Prospective evaluation of this 
genomics-based diagnostic algorithm in 5145 lung cancer 
patients yielded 75% diagnosis, which confirmed the 
rational reassignment of LC. The diagnostic signature 
also markedly improved overall survival in patients 
harboring EGFR mutations or anaplastic lymphoma 
kinase rearrangement. To conclude, this study provided 
a blueprint for genomic lung cancer diagnosis and 
supported the introduction of a molecular diagnosis in 
combination with specific therapeutic intervention.
Project TCLCG & Network Genomic Medicine A 
Genomics-Based Classification of Human Lung Tumors. 
Science Translational Medicine 2013;5:209ra153.
neWs In BRIeF
•	 World Conference on Lung 
Cancer (WCLC) 2013: 
Treatment with Therapies 
Matched to Oncogenic 
Drivers Improves survival 
in Patients with Lung 
Cancers: Results from The 
Lung Cancer Mutation 
Consortium (LCMC)
gene and 733 for all 10 genes. Sixty-four percent of 
the tumors bear an oncogenic driver: KRAS (25%), 
sensitizing EGFR (17%), anaplastic lymphoma kinase 
rearrangements (8%), and less than 5% for each of 
the following: other EGFR, HER2, BRAF, PIK3CA, 
MET amplification, NRAS, MEK1, and AKT1. 
Three percent bear more than one driver. The median 
survivals were 3.5 years for patients with an oncogenic 
driver treated with genotype-directed therapy, 2.4 years 
for those with an oncogenic driver without genotype-
directed therapy, and 2.1 years for those without any 
identified oncogenic driver. Multiplexed testing has 
enabled targeted therapy in 28% of the patients. The 
findings demonstrated improved survival in lung 
cancer patients harboring oncogenic drivers treated 
with matching targeted therapy.
•	 new Genetic Variants 
Identified for esophageal 
Cancers
A genome-wide association study published in Nature Genetics 
demonstrated a link between four genetic variations and the risk of 
developing esophageal adenocarcinoma and precancerous Barrett’s 
esophagus. From 2390 cases of esophageal adenocarcinoma, 3175 
individuals with precancerous Barrett’s esophagus, and 10,120 
controls significant association with three new variants were identified: 
The authors of this study aim to determine the genome alterations of 
clinically relevant subgroups in 1255 lung tumors across histological 
subtypes for genomic lung cancer diagnosis using comprehensive 
copy number analyses together with focused sequencing and RNA 
expression analysis. More than half of these tumors harbored at 
least one oncogenic alteration, to which targeted intervention or 
personalized therapies were developed and some are being assessed in 
clinical trials. For instance, EGFR mutations or anaplastic lymphoma 
kinase rearrangements in squamous cell carcinomas. The findings 
showed that the pattern of genomic alterations between and within 
At the plenary session of the World Conference on Lung Cancer 
2013, the results from the Lung Cancer Mutation Consortium, 
in which multiplexed assays were used to detect modifications 
in 10 oncogenic driver genes to guide clinical decisions on 
treatments and clinical trials were presented. Of the patients with 
metastatic lung adenocarcinoma enrolled at 14 Lung Cancer 
Mutation Consortium sites, 1007 were genotyped for at least one 
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obtained from the national cancer registry. The results 
showed that small nodules (volume <100 mm3 or 
diameter < 5 mm) are not predictive for lung cancer 
whereas large nodules (volume ≥ 300 mm3 or diameter 
≥ 10 mm) call for immediate diagnostic assessment. 
Volume-doubling time evaluation is required only for 
nodules of intermediate sizes (volume 100–300 mm3 
or diameter 5–10 mm). The authors estimated fewer 
follow-up CT assessments (29.8%–22.2%) and fewer 
additional diagnostic evaluation (8.9%–5.3%) with high 
sensitivity (94.2%) by raising the thresholds for ACCP 
recommended nodule size for an indeterminate result (4 
mm–5 mm) and a positive result (8 mm–10 mm).
•	 WCLC 2013: MesoVATs 
Trial of Video-Assisted 
Thoracoscopic 
Pleurectomy versus Talc 
Pleurodesis in Malignant 
Pleural Mesothelioma
at thoracoscopy. VAT pleurectomy involved partial 
parietal pleurectomy and decortication of the visceral 
pleura. There were 87 VAT pleurectomies and 88 talc 
pleurodeses for the main analysis, which included 
epithelioid disease (84%), IMIG stage 3/4 (78%), and 
high risk as per EORTC criteria (49%). The results 
showed significant improved control of pleural effusion 
(p = 0.008 at 1 month; p = 0.04 at 6 months) and 
improved quality of life (p = 0.042 at 6 months; p = 
0.006 at 12 months) in the VAT pleurectomy group. But 
the same group did not show improved overall survival 
(hazard ratio 1.03; p = 0.83), had longer hospital stay (p 
< 0.001), and experienced more complications (mainly 
prolonged air leak, p = 0.009). Further subgroup 
analyses are warranted to determine the intervention 
that will most benefit patients with MPM.
•	 WCLC 2013: Lung 
Cancer Probability in 
subjects with CT-Detected 
Pulmonary nodules
Horeweg and colleagues proposed a new and improved nodule 
management algorithm for lung cancer computed tomography 
(CT) screening based on lung cancer probability. Diameter, 
volume, and volume-doubling time (VDT) of 9.681 nodules 
detected by CT screening was assessed for the calculation of 
lung cancer probability. Complete lung cancer diagnoses were 
The findings from MesoVATS, a multicenter randomized controlled 
trial of evaluating video-assisted thoracoscopic (VAT) pleurectomy 
versus talc pleurodesis in controlling pleural effusion and improving 
survival in patients with malignant pleural mesothelioma (MPM), 
were presented at the World Conference on Lung Cancer 2013. 
Patients with more than 18 years of confirmed or suspected MPM 
with a pleural effusion were enrolled and risk-stratified. Talc 
pleurodesis involved the use of tube thoracostomy or poudrage 
•	 WCLC 2013: An 
Intergroup Randomized 
Phase III Comparison of 
standard-Dose (60 Gy) 
versus high-Dose (74 Gy) 
Chemoradiotherapy (CRT) 
+/− Cetuximab (Cetux) for 
stage III non–small-Cell 
Lung Cancer (nsCLC): 
Results on Cetux from 
RTOG 0617
standard-dose and high-dose arms demonstrated median 
survival times of 28.7 versus 19.5 months and 18-month 
OS rates of 66.9% versus 53.9%, respectively (hazard 
ratio, [HR] = 1.56, p = 0.0007). This was an initial 
report of survival outcome from the addition of cetux 
to CRT. Patients received concurrent CRT that included 
carboplatin and paclitaxel, and were randomized 
to cetux. There were 419 and 465 patients eligible 
for radiotherapy and cetux analyses with a median 
follow-up of 18.7 months. The OS data revealed that 74 
Gy is not superior to and could be worse than 60 Gy in 
treating stage III non–small-cell lung cancer patients 
receiving CRT. The addition of cetux to CRT did not 
improve survival: There were similar 18-month OS rates 
(HR = 0.99, p = 0.484) and median survival with and 
without cetux.
The RTOG 0617 trial aims to compare the overall survival (OS) of 
standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy with 
concurrent chemotherapy, and the addition of cetuximab (cetux) to 
standard chemoradiotherapy (CRT). It was previously reported that 
